About Orexin/Hypocretin receptor type 1
Orexin/Hypocretin receptor type 1 (HCRTR1) is a protein
from Homo sapiens identified by UniProt accession
O43613, 425 residues long.
MolForge cross-references it against 0 known binders and
183 disease associations.
Target properties
| Protein name | Orexin/Hypocretin receptor type 1 |
| UniProt accession | O43613 |
| Gene | HCRTR1 |
| Organism | Homo sapiens |
| Length | 425 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (183)
Diseases linked to this target (Open Targets).
- insomnia · score 0.59
- Sleep Disorder · score 0.50
- post-traumatic stress disorder · score 0.40
- panic disorder · score 0.37
- intelligence · score 0.36
- FEV/FVC ratio · score 0.33
- cognitive function measurement · score 0.32
- self reported educational attainment · score 0.30
- alcohol dependence · score 0.28
- delirium · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43613-F1 | alphafold | PREDICTED | 78.81 | — |
Amino-acid sequence (425 residues)
MEPSATPGAQ MGVPPGSREP SPVPPDYEDE FLRYLWRDYL YPKQYEWVLI AAYVAVFVVA LVGNTLVCLA VWRNHHMRTV TNYFIVNLSL ADVLVTAICL PASLLVDITE SWLFGHALCK VIPYLQAVSV SVAVLTLSFI ALDRWYAICH PLLFKSTARR ARGSILGIWA VSLAIMVPQA AVMECSSVLP ELANRTRLFS VCDERWADDL YPKIYHSCFF IVTYLAPLGL MAMAYFQIFR KLWGRQIPGT TSALVRNWKR PSDQLGDLEQ GLSGEPQPRA RAFLAEVKQM RARRKTAKML MVVLLVFALC YLPISVLNVL KRVFGMFRQA SDREAVYACF TFSHWLVYAN SAANPIIYNF LSGKFREQFK AAFSCCLPGL GPCGSLKAPS PRSSASHKSL SLQSRCSISK ISEHVVLTSV TTVLP
Explore Orexin/Hypocretin receptor type 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets